📊 COCP Key Takeaways
Is Cocrystal Pharma, Inc. (COCP) a Good Investment?
Cocrystal Pharma exhibits severe financial distress with collapsing revenue (-69.3% YoY), massive operating losses (-$6.5M), and negative free cash flow despite holding $7.7M in cash. The company's long-term debt of $49.9M far exceeds stockholders' equity, creating unsustainable leverage that threatens viability without significant operational turnaround or capital injection.
Cocrystal Pharma's fundamentals are weak: revenue fell sharply, margins are deeply negative, and the business continues to consume cash with no evidence of operating leverage. While liquidity appears adequate in the near term due to a solid cash balance and high current ratio, the combination of persistent losses, negative free cash flow, and very high reported leverage materially weakens financial quality.
Why Buy Cocrystal Pharma, Inc. Stock? COCP Key Strengths
- Maintains adequate liquidity with 5.78x current ratio and $7.7M cash on hand
- Positive gross margin of 100.4% indicates viable product economics when revenue materializes
- 13 Form 4 insider filings suggest management engagement, though activity level does not offset fundamental concerns
- Strong near-term liquidity with $7.73M in cash and a 5.78x current ratio
- Asset-light operating profile with minimal capital expenditure requirements
- Positive gross profit indicates some non-zero revenue base despite low scale
COCP Stock Risks: Cocrystal Pharma, Inc. Investment Risks
- Revenue collapse of 69.3% YoY indicates failed clinical trials, loss of partnerships, or failed commercialization
- Debt-to-equity ratio of 6.51x with long-term debt of $49.9M versus equity of $7.6M indicates bankruptcy risk within 12-18 months without turnaround
- Negative operating cash flow of -$6.5M and free cash flow margin of -321.2% means cash burn will deplete reserves within approximately 14 months at current burn rate
- Pharmaceutical sector typically requires years to achieve profitability; current trajectory unsustainable
- Revenue declined 69.3% year over year, indicating poor growth quality and weak commercial traction
- Operating loss of $6.54M and negative free cash flow of $6.47M suggest ongoing cash burn without profitability visibility
- Reported long-term debt of $49.94M and debt/equity of 6.51x imply severe balance-sheet risk, especially given the small equity base
Key Metrics to Watch
- Quarterly revenue trend and pipeline progress announcements
- Monthly cash burn rate and runway to profitability or financing event
- Debt covenant compliance and refinancing requirements
- Quarterly revenue trend and durability of collaboration or licensing income
- Cash runway, operating cash burn, and any clarification of debt versus total liabilities
Cocrystal Pharma, Inc. (COCP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.78x current ratio provides a solid financial cushion.
COCP Profit Margin, ROE & Profitability Analysis
COCP vs Healthcare Sector: How Cocrystal Pharma, Inc. Compares
How Cocrystal Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cocrystal Pharma, Inc. Stock Overvalued? COCP Valuation Analysis 2026
Based on fundamental analysis, Cocrystal Pharma, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cocrystal Pharma, Inc. Balance Sheet: COCP Debt, Cash & Liquidity
COCP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cocrystal Pharma, Inc.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
COCP Revenue Growth, EPS Growth & YoY Performance
COCP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $489.0K | -$2.0M | N/A |
| Q2 2021 | $554.0K | -$2.0M | N/A |
| Q1 2021 | $461.0K | -$2.0M | $-0.04 |
| Q3 2020 | $489.0K | -$324.0K | N/A |
| Q2 2020 | $554.0K | $1.5M | $0.05 |
| Q1 2020 | $461.0K | -$2.0M | $-0.05 |
| Q3 2019 | $492.0K | -$324.0K | N/A |
| Q2 2019 | $592.0K | -$1.3M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cocrystal Pharma, Inc. Dividends, Buybacks & Capital Allocation
COCP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cocrystal Pharma, Inc. (CIK: 0001412486)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COCP
What is the AI rating for COCP?
Cocrystal Pharma, Inc. (COCP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COCP's key strengths?
Claude: Maintains adequate liquidity with 5.78x current ratio and $7.7M cash on hand. Positive gross margin of 100.4% indicates viable product economics when revenue materializes. ChatGPT: Strong near-term liquidity with $7.73M in cash and a 5.78x current ratio. Asset-light operating profile with minimal capital expenditure requirements.
What are the risks of investing in COCP?
Claude: Revenue collapse of 69.3% YoY indicates failed clinical trials, loss of partnerships, or failed commercialization. Debt-to-equity ratio of 6.51x with long-term debt of $49.9M versus equity of $7.6M indicates bankruptcy risk within 12-18 months without turnaround. ChatGPT: Revenue declined 69.3% year over year, indicating poor growth quality and weak commercial traction. Operating loss of $6.54M and negative free cash flow of $6.47M suggest ongoing cash burn without profitability visibility.
What is COCP's revenue and growth?
Cocrystal Pharma, Inc. reported revenue of $2.0M.
Does COCP pay dividends?
Cocrystal Pharma, Inc. does not currently pay dividends.
Where can I find COCP SEC filings?
Official SEC filings for Cocrystal Pharma, Inc. (CIK: 0001412486) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COCP's EPS?
Cocrystal Pharma, Inc. has a diluted EPS of $-0.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COCP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cocrystal Pharma, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is COCP stock overvalued or undervalued?
Valuation metrics for COCP: ROE of -83.5% (sector avg: 15%), net margin of -318.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy COCP stock in 2026?
Our dual AI analysis gives Cocrystal Pharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COCP's free cash flow?
Cocrystal Pharma, Inc.'s operating cash flow is $-6.5M, with capital expenditures of $12.0K. FCF margin is -321.2%.
How does COCP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -318.0% (avg: 12%), ROE -83.5% (avg: 15%), current ratio 5.78 (avg: 2).
Is Cocrystal Pharma, Inc. carrying too much debt?
COCP has a debt-to-equity ratio of 6.51x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 5.78 suggests adequate short-term liquidity.